| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 05/11/2006 | US20060099191 Cell-seeded tissue-engineered polymers for treatment of intracranial aneurysms |
| 05/11/2006 | US20060099189 Anti-cancer virus desensitization method |
| 05/11/2006 | US20060096500 Microcrystalline cewllulose compositions |
| 05/11/2006 | CA2586033A1 The use of a protease or a protease inhibitor for the manufacture of medicaments |
| 05/11/2006 | CA2582159A1 Polyamine compositions |
| 05/10/2006 | EP1654380A2 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
| 05/10/2006 | EP1654364A2 Inactivated host cell delivery of polynucleotides encoding immunogens |
| 05/10/2006 | EP1654260A2 6-menbered heteroaryl compounds for the treatment of neurodegenerative disorders |
| 05/10/2006 | EP1654231A2 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 05/10/2006 | EP1654045A2 Building element for constructing a modular substructure |
| 05/10/2006 | EP1654005A2 Stable radiopharmaceutical compositions and methods for preparation |
| 05/10/2006 | EP1654003A2 Preventative effects of morinda citrifolia on mammary breast cancer |
| 05/10/2006 | EP1653988A2 Leukocyte internalized peptide-drug conjugates |
| 05/10/2006 | EP1653987A2 Host defense factor x (hdfx) |
| 05/10/2006 | EP1653986A2 Treatment of cancers expressing p95 erbb2 |
| 05/10/2006 | EP1653985A2 Conformationally constrained parathyroid hormone (pth) analogs |
| 05/10/2006 | EP1653969A2 Pyrrolo 1,2-b pyridazine derivatives |
| 05/10/2006 | EP1653962A2 Pyrazine modulators of cannabinoid receptors |
| 05/10/2006 | EP1653959A2 Lipid-modified immune response modifiers |
| 05/10/2006 | EP1653955A2 Hydroxylamine substituted imidazo-containing compounds |
| 05/10/2006 | EP1653953A2 Drug delivery methods and devices |
| 05/10/2006 | EP1653914A2 Oxime substituted imidazo-containing compounds |
| 05/10/2006 | EP1653912A2 Vaccine immunotherapy for immune suppressed patients |
| 05/10/2006 | EP1624899A4 Increased transduction using abc transporter substrates and/or inhibitors |
| 05/10/2006 | EP1587924A4 Methods for site-directed mutagenesis and targeted randomization |
| 05/10/2006 | EP1450834B9 Allium sativum bulb absolutes and therapeutic or cosmetic uses |
| 05/10/2006 | EP1290136B1 Probiotics for pet food applications |
| 05/10/2006 | EP1194525B1 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 05/10/2006 | EP1104403B1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 05/10/2006 | CN1771057A Releasable polymeric conjugates based on biodegradable linkers |
| 05/10/2006 | CN1771053A Immunoglobulin formulation and method of preparation thereof |
| 05/10/2006 | CN1771052A Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections |
| 05/10/2006 | CN1771049A Somatostatin-dopamine chimeric analogs |
| 05/10/2006 | CN1771031A Treating androgen deficiency in female (ADIF)-associated conditions with SARMS [ |
| 05/10/2006 | CN1770978A Treatment of HSV-related pathologies using ssDNA |
| 05/10/2006 | CN1770975A Method of promoting cell viability |
| 05/10/2006 | CN1255049C Functional agent for decomposing nicotine and method of preparing the same |
| 05/09/2006 | WO2004112700A3 Methods and compositions for modulating amyloid precursor protein translation |
| 05/09/2006 | US7041679 Crystallization, filtration; neurokinins receptor antagonist |
| 05/09/2006 | US7041312 Wound healing compositions and methods of use |
| 05/09/2006 | US7041299 vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain that lack the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. |
| 05/09/2006 | US7041287 Comprises anticoagulant/thrombolytic agent for selective dissolution of fibrin clots |
| 05/09/2006 | US7041277 Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same |
| 05/04/2006 | WO2006046910A1 Novel use |
| 05/04/2006 | WO2006046243A1 Sv40 for gene therapy of renal disorders |
| 05/04/2006 | WO2005063169A3 Medical lipolysis of fat accumulations |
| 05/04/2006 | WO2005053611A3 Treatment of phosphatidylinositol phospholipid disorders |
| 05/04/2006 | WO2005048944A3 Activatable photodynamic therapy agents |
| 05/04/2006 | WO2005037204A3 Ntrk1 genetic markers associated with age of onset of alzheimer's disease |
| 05/04/2006 | WO2005011583A8 Treatment of allergic rhinitis and asthma |
| 05/04/2006 | US20060094783 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
| 05/04/2006 | US20060094762 Magnesium salt of imidazole derivative |
| 05/04/2006 | US20060094740 Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| 05/04/2006 | US20060094726 Quinoline derivatives as nk-2 and nk-3 receptor antagonists |
| 05/04/2006 | US20060094658 Method and compositions for the treatment of gastrointestinal disorders |
| 05/04/2006 | US20060094017 Immunogens for hiv vaccine |
| 05/04/2006 | US20060093680 Coated particles and pharmaceutical dosage forms |
| 05/04/2006 | US20060093626 Lyophilization; conjugated Streptococcus pneumoniae capsular polysaccharide serotype is adjuvanted with 3-0 deacylated monophosphoryl lipid A (3D-MPL) and devoid of aluminium-based adjuvant |
| 05/03/2006 | EP1651956A2 Melks as modifiers of the rac pathway and methods of use |
| 05/03/2006 | EP1651648A2 Compounds and compositions as protein kinase inhibitors |
| 05/03/2006 | EP1651643A2 Bicyclic compounds and compositions as pdf inhibitors |
| 05/03/2006 | EP1651628A2 Antibiotic compound |
| 05/03/2006 | EP1651623A2 Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 05/03/2006 | EP1651271A2 Compositions and methods for treating coronavirus infection and sars |
| 05/03/2006 | EP1651269A2 Monoclonal antibodies against ricin toxin and methods of making and using thereof |
| 05/03/2006 | EP1651258A2 Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
| 05/03/2006 | EP1651235A2 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
| 05/03/2006 | EP1651216A2 Infection prophylaxis using immune response modifier compounds |
| 05/03/2006 | EP1651211A2 Combination of drugs for the treatment of neoplasms |
| 05/03/2006 | EP1651209A2 Tyrosine kinase inhibitors |
| 05/03/2006 | EP1651190A2 Formulations containing an immune response modifier |
| 05/03/2006 | EP1651187A2 Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
| 05/03/2006 | EP1651170A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 05/03/2006 | EP1651166A2 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 05/03/2006 | EP1651164A2 Composition and method for treating neurological disorders |
| 05/03/2006 | EP1651163A2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
| 05/03/2006 | EP1651161A2 Pharmaceutical compositions and methods for accelerating wound healing |
| 05/03/2006 | EP1651136A2 Method for the preparation of controlled release formulations |
| 05/03/2006 | EP1490049B1 Citalopram for the treatment of elevated blood pressure |
| 05/03/2006 | EP1425005B1 Pharmaceutical compostion comprising lumiracoxib |
| 05/03/2006 | EP1381358B1 Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp |
| 05/03/2006 | EP1267829B1 Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent |
| 05/03/2006 | EP1194404B1 Inhibitors of aspartyl protease |
| 05/03/2006 | CN1767847A Treatment of aspergillus infections with thymosin alpha 1 |
| 05/03/2006 | CN1767843A Method for preparing antimicrobial agent and antioxidant position from sea-buckthorn seeds |
| 05/03/2006 | CN1767835A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 05/03/2006 | CN1767834A Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 05/03/2006 | CN1767824A Photostabilized topical formulations of KETOPROFEN |
| 05/03/2006 | CN1765899A Diazabicyclic central nervous system active agents |
| 05/03/2006 | CN1765891A Novel aryloxy-alkyl-dialkylamines compound |
| 05/03/2006 | CN1254470C Process for preparation of baccatin III derivatives |
| 05/02/2006 | US7038085 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 05/02/2006 | US7038070 Coordination polymerization catalysts |
| 05/02/2006 | US7038038 Coupling silylated 5-azacytosine to a protected ribofuranose using trimethylsilyl trifluoromethane catalyst; cooling, accumulation by filtration, quenching, solvent extraction |
| 05/02/2006 | US7037940 Taxol enhancer compounds |
| 05/02/2006 | US7037917 Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases |
| 05/02/2006 | US7037909 Tetracyclic compounds as c-Met inhibitors |
| 05/02/2006 | US7037908 HIV integrase inhibitors |
| 05/02/2006 | US7037668 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616 |
| 05/02/2006 | US7037533 Functional agent for decomposing nicotine and method of preparing the same |